Cover Image

O3 Heme-arginate as a latency-reversing agent for HIV-1 cure

Saved in:

Bibliographic Details
Main Authors:	Michaela Madlenakova (Author), Prakash Shankaran (Author), Vera Hajkova (Author), David Jilich (Author), Ladislav Machala (Author), Pavel Martasek (Author), Zora Melkova (Author)
Format:	Book
Published:	Elsevier, 2017-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of heme degradation products on reactivation of latent HIV-1
by: Z. Melkova, et al.
Published: (2015)

Prophylactic Heme Arginate Infusion for Acute Intermittent Porphyria
by: Hung-Chou Kuo, et al.
Published: (2021)

Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure
by: G. Clutton, et al.
Published: (2015)

Approaches to discover latency-reversing agents
Published: (2015)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019)

PP 2.13 - 00160 Enhancing Tolerability and Efficacy of Latency Reversing Agents in "Kick and Kill" HIV Cure Approaches
by: J. Moran, et al.
Published: (2022)

Identification of a promising new class of latency reversing agents
by: A. Gramatica, et al.
Published: (2017)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019)

SMAC mimetics are potent latency reversal agents with single agent and combination activity ex vivo
by: R.M. Dunham, et al.
Published: (2017)

Novel use of alprazolam as a potential HIV-1 latency reversing agent
by: W. Elbezanti, et al.
Published: (2017)

Tissue-specific effects of latency-reversing agents on HIV transcriptional blocks in gut and blood
by: S. Telwatte, et al.
Published: (2019)

OP 2.8 - 00193 Enhancing PKC Modulator HIV Latency Reversing Agents
by: M. Marsden, et al.
Published: (2022)

Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells
by: Melanie Dimapasoc, et al.
Published: (2024)

Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016)

Latency-reversing agents and cellular activation affect antigen processing in primary CD4 T cells
by: J. Boucau, et al.
Published: (2015)

PP 5.4 - 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
by: L. Pache, et al.
Published: (2022)

A theoretical framework to guide clinical trial design to estimate efficacies of latency-reversing agents
by: R. Ke, et al.
Published: (2015)

Memory CD4+ T cell subsets show differential responses to HIV latency-reversing agents
by: D.A. Kulpa, et al.
Published: (2015)

Efficacy of NovaMin- and Pro-Argin-containing desensitizing dentifrices on occlusion of dentinal tubules
by: Shivani Shah, et al.
Published: (2017)

P1 Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro latency models
by: Pawel Bonczkowski, et al.
Published: (2016)

HIV latency reversal using designed PKC modulators
by: M.D. Marsden, et al.
Published: (2017)

24 Thalidomide reverses latency of HIV-1 provirus
by: S. Samer, et al.
Published: (2016)

The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review
by: Quinten Debrabander, et al.
Published: (2023)

PP 2.9 - 00125 Impact of latency reversal agents on estrogen receptor alpha gene and protein expression
by: C. Ceriani, et al.
Published: (2022)

26 A novel assay to evaluate the response of patient-derived virus to latency-reversing agents ex vivo
by: H. Lu, et al.
Published: (2016)

Patient-derived HIV reservoirs can be stably engrafted into NSG mice and reactivated by latency-reversing agents in vivo
by: A. Ward, et al.
Published: (2017)

Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening
by: Donya Naz Divsalar, et al.
Published: (2020)

O6 Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016)

The reduction efficacy of dentinal hypersensitivity by two commercially available desensitizing toothpastes: Vantej and Colgate Pro- Argin
by: Aditya Rao, et al.
Published: (2014)

Insights into mechanisms of HIV reactivation from latency using RNA-Seq gene expression profiling in CD4+ T cells and their maturation subsets following treatment with latency reversing agents.
by: N. Beliakova-Bethell, et al.
Published: (2017)

Novel SHIVs encoding transmitted/founder envs for latency and cure research
by: K. Bar, et al.
Published: (2017)

Novel SHIVs encoding transmitted/founder Envs for latency and cure research
by: A. Bauer, et al.
Published: (2019)

Lymphoid tissue and blood CD4 T cells respond differently to latency-reversing agents: are we testing the right cells?
by: A. Gramatica, et al.
Published: (2015)

The SMAC mimetic AZD5582 reverses HIV latency as a single agent in resting primary CD4+ T cells
by: G. Sampey, et al.
Published: (2019)

21 Patient-derived HIV reservoirs can be stably engrafted into NSG mice and reactivated by latency-reversing agents in vivo
by: Adam Ward, et al.
Published: (2017)

CL572, a potent agonist of Toll-like receptor 2/7, as a novel latency-reversing agent
by: A. Macedo, et al.
Published: (2015)

Co-culture of T-cells with dendritic cells facilitates HIV latency in proliferating CD4+ T-cells: implications for the establishment and reversal of latency
by: N. Kumar, et al.
Published: (2015)

Integration site-independent enhancement of latency reversal by HIV-1 Nef
by: X.T. Kuang, et al.
Published: (2017)

Cleavage and polyadenylation specific factor 6 is required for HIV latency reversal
by: Y. Zheng, et al.
Published: (2019)